Latest News

Mana.bio showcases groundbreaking advancements in LNP safety, potency, and tolerability, setting a new standard for gene therapy delivery systems.

Mana.bio announces a strategic partnership with Sheba Medical Center, ARC to advance RNA therapies for cancer and autoimmune diseases, leveraging AI-driven LNP technology.

Mana.Bio has been recognized by TheMarker as one of Israel’s top 20 most promising startups, highlighting its groundbreaking LNP technology and commitment to innovative RNA delivery solutions.

Host Surani Fernando speaks with our CEO Yogev Debbi and fully explores our multi-layered start-up story including our origin, lab research and the challenges of launching the organization from stealth in October 2023 in the midst of the attacks on Israel.

Mana Joins the NVIDIA Inception Program to Drive AI Innovation, Enhance RNA Delivery Technologies, and Collaborate with Leading Startups.

Mana joins the Ginkgo Technology Network, leveraging integrated R&D capabilities alongside over 25 partners to drive innovation in AI, genetic medicines, biologics, and manufacturing, enhancing collaborative efforts and accelerating advancements in these fields.

The company is employing AI to design lipid nanoparticles (LNPs) with the goal of creating programmable drug treatments

One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Little balls of fat called lipid nanoparticles used to carry mRNA can be injected into the arm for vaccines or infused into the blood to shuttle genetic medicines to the liver. But delivering the molecules to other cells or organs remains a challenge.

Mana.bio’s first-of-its-kind AI platform discovers and optimizes novel, customizable LNPs for tissue-specific delivery of nucleic acid-based therapeutics and vaccines, today announcing its seed funding

With the opportunity to treat spades of infectious diseases, cancers and single gene disorders, there is enormous potential in RNA therapeutics. To realize it, however, researchers will need to optimize delivery to on-target cells, minimize exposure to off-target cells and move beyond the liver.

Starting a TechBio company is a rewarding challenge. In this episode Yogev Debbi, Co-founder and CEO at Mana.bio enjoys discussing it with Omri Amirav-Drory from NFX, his co-founder from their first TechBio company Genome Compiler and now an investor at Mana.bio where we're disrupting Drug Delivery using ML/AI.

An agreement to embed chemical substance data from the CAS Content CollectionTM directly into the Mana.bio AI data acquisition workflow via an application programmable interface (API). This collaboration will enrich Mana.bio’s proprietary database to fuel its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.